CORE--TUMOR BANK

核心——肿瘤库

基本信息

  • 批准号:
    7142525
  • 负责人:
  • 金额:
    $ 3.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-10 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

The Tumor Bank Facility (TBF) is a centralized resource for Fox Chase Cancer Center (FCCC) designated as the source of normal and tumor tissues for cancer research. The TBF is responsible for collecting, banking, and distributing normal and tumor specimens (fresh, frozen, or paraffin-embedded) accrued from consented patients treated surgically at FCCC. Accrual has increased 50% since the year of our last review (500 in 1999 versus 751 specimens in 2003). Usage of frozen samples has stabilized around 600 samples a year, peaking at 848 in 2002 (range during the last four years: 569-848 samples per year). The annual usage of paraffin sections of human tissues has stabilized between 2,000-4,000, whereas cut paraffin tissue microarray (TMA) sections grew steadily to 150 in 2003 and 2004 shows continued growth. In addition, the TBF continues to provide comprehensive pathology support, both at the technical and interpretative levels for FCCC investigators. Since our last review, the following new policies and services have been implemented: 1) a new Prioritization Subcommittee has been established, 2) we have increased the number of accrued tissues and their respective aliquots, 3) we introduced TMAs and extraction of nucleic acids from normal and neoplastic tissues to minimize depletion of our banked specimens. The introduction of TMAs has been very successful and has helped to reduce depletion of valuable tissues. A total of 35 TMAs are now available (total 1,891 tissue cores). We have distributed 40 TMA sections in 2002 and 149 sections in 2003. Similarly, we have started extracting and distributing nucleic acids to three investigators (total 73 samples in 2003. 4) A new Web-based data entry-system and database has been created. The TBF works closely with the Population Studies Facility to ensure that critical clinical information is linked to each of our de-identified tissue specimens. All our donors have been consented following NIH guidelines. The Facility follows the established guidelines of quality control (QC) and tissues are distributed only to IRB-approved projects. Furthermore, all operations, prioritization and distribution activities are overseen by the Tumor Bank and Biosample Repository Advisory Committee. This Facility is utilized by 24 peer-reviewed investigators from seven different Programs in all three Divisions. Seventy-seven percent (77%) of its use is by investigators with peer-reviewed funding.
肿瘤银行设施(TBF)是福克斯大通癌症中心(FCCC)的集中资源 被指定为癌症研究的正常和肿瘤组织的来源。TBF负责收集、储存和分发来自同意在FCCC接受手术治疗的患者的正常和肿瘤标本(新鲜、冷冻或石蜡包埋)。自我们上次审查以来,应计数量增加了50%(1999年为500份,2003年为751份)。冷冻样本的使用稳定在每年600个样本左右,2002年达到高峰,为848个(过去四年的范围:每年569-848个样本)。人体组织的石蜡切片的年使用量稳定在2,000 - 4,000之间,而切割石蜡组织微阵列(TMA)切片在2003年稳定增长到150,2004年显示出持续增长。此外,TBF继续为气候变化框架公约调查人员提供全面的病理学支持,包括技术支持和解释支持。自上次审查以来,我们实施了以下新政策和服务:1)成立了新的优先级小组委员会,2)我们增加了累积组织及其相应等分试样的数量,3)我们引入了TMA并从正常和肿瘤组织中提取核酸,以尽量减少库存标本的消耗。TMA的引入非常成功,并有助于减少有价值组织的消耗。目前共有35个TMA可用(共1,891个组织芯)。我们在2002年和2003年分别分发了40份和149份《东京都市报》。同样,我们已开始提取核酸并分发给三名调查员(2003年共73个样本)。4)一个新的基于网络的数据输入系统和数据库已经建立。TBF与人口研究机构密切合作,以确保关键临床信息与我们的每个去识别组织标本相关联。我们所有的捐赠者都同意遵守NIH的指导方针。该机构遵循既定的质量控制(QC)指南,组织仅分发给IRB批准的项目。此外,所有操作、优先排序和分发活动均由肿瘤库和生物样本库咨询委员会监督。24个经同行审查的机构利用了这一机制。 来自三个部门七个不同项目的调查员。百分之七十七 (77%)的使用是由研究人员与同行评审的资金。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert C Young其他文献

Anticholinergic effects and plasma desipramine levels
抗胆碱能作用和血浆地昔帕明水平
Age and Serum Fluphenazine Concentrations
年龄与氟奋乃静血清浓度
  • DOI:
    10.1038/sj.npp.1380230
  • 发表时间:
    2003-07-25
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    James J Weisbard;Robert C Young
  • 通讯作者:
    Robert C Young

Robert C Young的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert C Young', 18)}}的其他基金

CORE--RESEARCH CYTOGENETICS
核心--研究细胞遗传学
  • 批准号:
    7142523
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--LAB ANIMAL HEALTH
核心--实验动物健康
  • 批准号:
    7141894
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--HISTOPATHOLOGY
核心--组织病理学
  • 批准号:
    7142512
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--GENETIC MONITORING
核心——基因监测
  • 批准号:
    7141890
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--DNA MICROARRAY FACILITY
核心——DNA微阵列设备
  • 批准号:
    7142491
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--MOLECULAR MODELING FACILITY
核心——分子模拟设施
  • 批准号:
    7142498
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--CELL SORTING
核心——细胞分选
  • 批准号:
    7142508
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--HYBRIDOMA
核心--杂交瘤
  • 批准号:
    7142516
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--CELL CULTURE
核心--细胞培养
  • 批准号:
    7142502
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
CORE--BIOSAMPLE REPOSITORY
核心--BIOSAMPLE存储库
  • 批准号:
    7142518
  • 财政年份:
    2005
  • 资助金额:
    $ 3.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了